Clinical Trial Update: A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas [Phase 2]

View source ↗

Summary

The document reports the completion of a Phase II trial evaluating adjuvant EGFR-425 therapy in high-grade gliomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma
• High-grade Glioma

Drugs mentioned

• EGFR-425

Snippet

Sponsor: Drexel University College of Medicine | Conditions: Gliomas | Phase 2 | Status: COMPLETED